Oncolytics Biotech
ONCY
41 hedge funds and large institutions have $3.87M invested in Oncolytics Biotech in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 7 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
49% more capital invested
Capital invested by funds: $2.59M → $3.87M (+$1.27M)
14% more funds holding
Funds holding: 36 → 41 (+5)
0.47% less ownership
Funds ownership: 2.51% → 2.04% (-0.47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$469K |
| 2 |
JP Morgan Chase
New York
|
+$168K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$147K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$123K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$415K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$268K |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$141K |
| 4 |
Two Sigma Advisers
New York
|
-$96.7K |
| 5 |
VF
Virtu Financial
New York
|
-$47K |
ONCY Hedge Fund Activity: Q1 2021 in Review
41 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2021, worth a combined $3.87M — up 49% from $2.59M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ONCY positions and 7 closed out — a net gain of 5 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was International Assets Investment Management, adding an estimated $469K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $415K sold.
- 41 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2021, up from 36 in Q4 2020.
- Funds reported $3.87M of Oncolytics Biotech stock for Q1 2021, up 49% quarter-over-quarter.
- 12 funds opened new Oncolytics Biotech positions in Q1 2021 and 7 closed out, a net change of +5 holders.
- The largest Oncolytics Biotech buyer in Q1 2021 was International Assets Investment Management, an estimated $469K added.
- The largest Oncolytics Biotech seller in Q1 2021 was Renaissance Technologies, an estimated $415K sold.
Based on aggregated 13F filings for Q1 2021.